Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:PGNY

Progyny Q3 2026 Earnings Date & Estimates

Progyny logo
$28.13 -0.84 (-2.90%)
Closing price 04:00 PM Eastern
Extended Trading
$28.13 0.00 (0.00%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Progyny is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for 4:45 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:45 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Progyny in Q3 2026

Progyny is expected to post earnings of $0.3130 per share on revenue of $340.76 million. In the same quarter a year earlier Progyny reported $0.45 per share on revenue of $313.35 million. Progyny last reported on August 6, 2026, posting $0.55 per share and beating the $0.3348 consensus estimate. Progyny has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.3130
Expected Revenue
$340.76 million
Prior-Year EPS
$0.45
Prior-Year Revenue
$313.35 million
Expected EPS Growth
-30.4%
Expected Revenue Growth
+8.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.55 (Beat by +$0.2152)
Last Quarter Revenue
$350.51 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Progyny Q3 2026 Earnings FAQ

Progyny (NASDAQ:PGNY) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Progyny's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 4:45 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Progyny to post earnings of $0.3130 per share for Q3 2026.

The consensus revenue estimate for Progyny is $340.76 million for Q3 2026.

Progyny Earnings Headlines

New Progyny Study Finds Significant Improvement in Menopause Symptoms Through Connected Care Model
October 26 at 11:25 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/26/3388341/0/en/new-progyny-study-finds-significant-improvement-in-menopause-symptoms-through-connected-care-model.html
Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385709/0/en/progyny-inc-announces-details-for-its-third-quarter-2026-results-report.html
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - and much of it sits beneath the desert near the Grand Canyon. A drilling crew just hit the DOE's 2035 targets twelve years early, with costs down 50% in 18 months. Google signed on, Gates invested, and the Pentagon made it a priority. One company has been quietly building this infrastructure for sixty years.tc pixel
October 26 at 1:00 AM  |  Behind the Markets (Ad)
Progyny (PGNY) Gets a Buy from Wells Fargo
October 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PGNY/pressreleases/8134671/progyny-pgny-gets-a-buy-from-wells-fargo/
Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Progyny (PGNY)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VTRS/pressreleases/8078355/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-and-progyny-pgny/
Leerink Partners Sticks to Its Buy Rating for Progyny (PGNY)
October 16, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8093936/leerink-partners-sticks-to-its-buy-rating-for-progyny-pgny/
See More Progyny Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Progyny? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Progyny and other key companies, straight to your email.

About Progyny

Progyny (NASDAQ:PGNY) is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States. The company was founded in 2015 and became a publicly traded company on the Nasdaq in 2019. Peter Anevski serves as chief executive officer, having previously held senior financial and operational roles at the company.

View Progyny Profile
Earnings Tools